GABG IV‐A‐93.

Methods	Multicentre trial.
Participants	771 pre‐menopausal women with hormone receptor positive tumours and no positive nodes were randomised.
Interventions	Patients were randomised to CMF (cyclophosphamide 500mg/m2 d1 and d8, methotrexate 40mg/m2 iv d1 and d8, and 5‐flourouracil 600mg/m2 iv d1 and d8) every 28 days for three cycles (n=378) versus goserelin 3.6mg every 28 days for two years (n=393).
Outcomes	Outcomes: local and distant recurrence and overall survival.
Notes	Global quality rating: A
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear